

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Wed May 30 15:01:33 EDT 2007

=====

Application No: 10573625 Version No: 1.0

Input Set:

Output Set:

Started: 2007-05-30 14:25:04.768  
Finished: 2007-05-30 14:25:05.110  
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 342 ms  
Total Warnings: 4  
Total Errors: 0  
No. of SeqIDs Defined: 5  
Actual SeqID Count: 5

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)

# SEQUENCE LISTING

<110> PROUDFOOT, AMANDA  
SHAW, JEFFREY  
JOHNSON, ZOE

<120> THERAPEUTIC USES OF CHEMOKINE VARIANTS

<130> ARS-124

<140> 10573625

<141> 2007-05-30

<150> US 10/573,625

<151> 2006-03-28

<150> EP 03078308

<151> 2003-10-16

<160> 5

<170> PatentIn version 3.0

<210> 1

<211> 76

<212> PRT

<213> Homo sapiens

<220>

<223> Human CCL2

<400> 1

Gln	Pro	Asp	Ala	Ile	Asn	Ala	Pro	Val	Thr	Cys	Cys	Tyr	Asn	Phe	Thr
1				5					10					15	

Asn	Arg	Lys	Ile	Ser	Val	Gln	Arg	Leu	Ala	Ser	Tyr	Arg	Arg	Ile	Thr
			20					25						30	

Ser	Ser	Lys	Cys	Pro	Lys	Glu	Ala	Val	Ile	Phe	Lys	Thr	Ile	Val	Ala
		35					40					45			

Lys	Glu	Ile	Cys	Ala	Asp	Pro	Lys	Gln	Lys	Trp	Val	Gln	Asp	Ser	Met
	50					55					60				

Asp	His	Leu	Asp	Lys	Gln	Thr	Gln	Thr	Pro	Lys	Thr
65					70					75	

<210> 2

<211> 76

<212> PRT

<213> Artificial sequence

<220>

<223> Human CCL2-P8A

<400> 2

Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr  
1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met  
50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
65 70 75

<210> 3

<211> 76

<212> PRT

<213> Artificial sequence

<220>

<223> Human CCL2\*

<400> 3

Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr  
1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile  
50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
65 70 75

<210> 4

<211> 76

<212> PRT

<213> Artificial sequence

<220>

<223> Human CCL2\*-P8A

<400> 4

Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr  
1 5 10 15

Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
 20 25 30

Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
 35 40 45

Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile  
 50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
 65 70 75

<210> 5  
 <211> 331  
 <212> PRT  
 <213> Artificial sequence

<220>  
 <223> Human CCL2-P8A\_IgG1 fusion protein

<400> 5

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr  
 1 5 10 15

Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Ala Val  
 20 25 30

Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu  
 35 40 45

Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val  
 50 55 60

Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln  
 65 70 75 80

Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr  
 85 90 95

Pro Lys Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro  
 100 105 110

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro  
 115 120 125

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr  
 130 135 140

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn  
 145 150 155 160

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg  
 165 170 175

Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val			
				180					185					190				
Leu	His	Asn	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser			
		195					200					205						
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys			
	210					215					220							
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu			
225					230					235					240			
Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe			
				245					250					255				
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Gln	Gly	Gln	Pro	Glu			
			260					265					270					
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe			
		275					280					285						
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly			
	290					295					300							
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr			
305					310					315					320			
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys								
				325				330										